MedTrace Logo

Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata

NCT05589610 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-04-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of 24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous (IV) push weekly.

Conditions

Interventions

DRUG

EQ101

EQ101, 2 mg/kg, once weekly dosing, for a total of 24 doses

Sponsors & Collaborators

  • Equillium AUS Pty Ltd

    collaborator UNKNOWN

  • Equillium

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-19
Primary Completion
2024-03-26
Completion
2024-04-30

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05589610 on ClinicalTrials.gov